Alvotech Aiming To Lead Competition On High-Dose Eylea Biosimilar
Icelandic Firm Manufacturing Scale-Up Batches; Follows EU Filing For Aflibercept 2mg
Regeneron’s Eylea 8mg, which offers less frequent dosing and is intended to act as a bulwark against biosimilar competition to the originator’s earlier 2mg version, is a target for biosimilar sponsor Alvotech. The Icelandic firm is aiming to lead the way in global markets.
